Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269059 | 0.92 | PIK3CD (0.34) | PIK3CDCYP1A2CYP3A4GAACYP2C9 | |
| SCHEMBL31269108 | 0.91 | PIK3CD (0.33) | PIK3CDCYP1A2CYP3A4GAACYP2C9 | |
| SCHEMBL31268764 | 0.90 | PIK3CD (0.33) | PIK3CDSMN1; SMN2 | |
| SCHEMBL31268953 | 0.90 | PDK2 (0.33) | PIK3CD | |
| SCHEMBL31268874 | 0.88 | KDM4E (0.32) | PIK3CD | |
| SCHEMBL31269111 | 0.87 | HRH4 (0.32) | PIK3CD | |
| SCHEMBL31269339 | 0.87 | PIK3CD (0.34) | PIK3CD | |
| SCHEMBL30983382 | 0.86 | PDE2A (0.34) | PIK3CD | |
| SCHEMBL30983510 | 0.86 | PDE2A (0.34) | PIK3CD | |
| SCHEMBL30983461 | 0.86 | PDE2A (0.34) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |